Drug Approval | November 02, 2024
USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Subscribe To Our Newsletter & Stay Updated
